MapLight Therapeutics Inc’s recent filing unveils that its 10% Owner Novo Holdings A/S acquired Company’s shares for reported $16.2 million on Oct 28 ’25. In the deal valued at $17.00 per share,952,941 shares were bought. As a result of this transaction, Novo Holdings A/S now holds 3,686,622 shares worth roughly $75.76 million.
Then, Catalyst4, Inc. bought 5,441,176 shares, generating $92,499,992 in total proceeds. Upon buying the shares at $17.00, the 10% Owner now owns 19,697,464 shares.
Stifel initiated its MapLight Therapeutics Inc [MPLT] rating to a Buy in a research note published on November 21, 2025; the price target was $28. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in late November with a ‘”an Overweight”‘ rating. Leerink Partners began covering MPLT with “an Outperform” recommendation on November 21, 2025. Jefferies started covering the stock on November 21, 2025. It rated MPLT as “a Buy”.
Price Performance Review of MPLT
On Friday, MapLight Therapeutics Inc [NASDAQ:MPLT] saw its stock jump 3.06% to $20.55. Over the last five days, the stock has lost -0.72%. Nevertheless, the stocks have risen 12.05% over the past one year.
Levels Of Support And Resistance For MPLT Stock
The 24-hour chart illustrates a support level at 19.82, which if violated will result in even more drops to 19.08. On the upside, there is a resistance level at 21.21. A further resistance level may holdings at 21.86.
How much short interest is there in MapLight Therapeutics Inc?
A steep rise in short interest was recorded in MapLight Therapeutics Inc stocks on 2025-11-28, growing by 0.56 million shares to a total of 0.76 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 0.2 million shares. There was a rise of 73.97%, which implies that there is a positive sentiment for the stock.
